Molecular Operating Environment (MOE™) Users Enjoy the Power of IBM Systems
MONTREAL, Dec. 19, 2003
The combination of Chemical Computing Group's Molecular Operating
Environment (MOE™) with IBM's comprehensive range of hardware platforms
is proving a powerful one in addressing problems in the drug discovery
industry. MOE has long been available on Linux and Windows, but an agreement
between CCG and IBM brought the power of MOE to AIX® Unix systems,
alongside support for MOE on IBM's powerful Linux cluster and
Intellistation® hardware products. MOE users are now enjoying the widest
possible choice of platforms, and benefiting from the speed and graphics
capabilities of IBM's pSeries® and xSeries® hardware. MOE is also now
capable of interacting with IBM's DB2® database software platform.
"I am having a very positive experience running MOE on an IBM
Intellistation® M-PRO under Linux," said Dr. Vincenzo Tschinke of Speedel
Group, a biopharmaceutical company based in Basel, Switzerland, speaking on
December 10th 2003. "The very responsive graphics and computational power of
this combination has allowed me to fully analyze close to a thousand molecules
in three dimensions -- including docking to protein binding sites and the
creation of predictive QSAR models -- in less than a year. The workstation has
been running error-free for over 300 days".
Now that the benefits of the collaboration are becoming clear, CCG and IBM
intend to continue to work together to enhance the efficiency and productivity
of drug discovery researchers.
Chemical Computing Group Inc. is a leading provider of
computational applications aimed at the drug discovery and design marketplace.
CCG's flagship product is the award winning Molecular Operating Environment
(MOE), which offers visualization, simulation, and methodology development in
one package. MOE provides an integrated suite of powerful, yet intuitive
chemistry software tools for HTS, structure-based design, molecular modeling,
protein and homology modeling, as well as an embedded programming language for
the rapid prototyping of scientific methods. Computational chemists, medicinal
chemists and biologists use MOE in pharmaceutical companies, biotechnology
companies, and universities worldwide. CCG is located in Montreal. Its web
site is www.chemcomp.com. E-mail inquiries can be sent to
The Speedel Group, based in Basel, Switzerland, is
a biopharmaceutical company with a core competence in drug development,
focusing on early proof-of-concept in man in cardiovascular and metabolic
diseases. These are the main causes of death in the industrialized world and
represent the largest pharmaceutical market segments worldwide. A privately
owned company formed in 1998, Speedel employs a team of over forty experienced
pharmaceutical scientists and managers in Europe, the United States and Japan.
Speedel in-licenses innovative drug candidates at late preclinical or early
clinical development stages and upon completion of proof-of-concept in man at
Phase II, Speedel partners with leading pharmaceutical companies for Phase III
development and commercialization. In addition, Speedel is a world-leader in
the area of renin inhibitors and through its research unit Speedel Experimenta
it generates novel development candidates and new Intellectual Property. For
additional information see www.speedelgroup.com.
"MOE" is a trademark of Chemical Computing Group Inc.
"AIX", "DB2", "pSeries", "xSeries" and "Intellistation" are registered
trademarks of IBM.